Evidence map›Paper›PMID 34831013›Full record

ArticleCancers2021

Tylectomy Safety in Salvage of Eyes with Retinoblastoma.

Junyang Zhao, Qiyan Li, Zhao Xun Feng, Jianping Zhang, Songyi Wu, Liwen Jin, Brenda L Gallie

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Junyang ZhaoDepartment of Ophthalmology, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou 545001, China.
Qiyan LiDepartment of Ophthalmology, Beijing Tongren Hospital, Beijing 100730, China.
Zhao Xun FengDepartment of Ophthalmology, University of Ottawa, Ottawa, ON K1L 8L6, Canada.
Jianping ZhangDepartment of Ophthalmology, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou 545001, China.
Songyi WuQuanzhou Aier Eye Hospital, Quanzhou 362017, China.
Liwen JinQuanzhou Aier Eye Hospital, Quanzhou 362017, China.
Brenda L GallieDepartment of Ophthalmology and Vision Science, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.ORCID 0000-0002-9697-9211
Liuzhou Maternal and Child Health Hospital · CNBeijing Tongren Hospital · CNUniversity Health Network · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraocular surgery is tabooed in retinoblastoma management, due to the concern of lethal extraocular spread. We reviewed the outcomes of consecutive children with intraocular retinoblastoma diagnosed at 29 Chinese centers between 2012-2014. We compared the outcomes of three categories of treatment: eye salvage including tylectomy (Group I), eye salvage without tylectomy (Group II), and primary enucleation (Group III). A total of 960 patients (1243 eyes) were diagnosed: 256 in Group I, 370 in Group II, and 293 in Group III; 41 patients abandoned treatment upfront. The estimated 5-year overall survivals (OS) were, for Group I, 94%, for Group II 89%, and for Group III 95%. The estimated 5-year disease-specific survivals (DSS) were, for Group I, 96%, for Group II 90%, and for Group III 95%. Patients in Group I had a significantly higher 5-year DSS than patients in Group II (

Indexed as

endoresectionenucleationpars plana vitrectomyresectionretinoblastomasafetysurgerysurvivaltylectomy

Identifiers

PMID34831013
PMCPMC8616183
OpenAlexW3215161852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.